This phase 2 randomized clinical trial investigates the safety of azithromycin for children with respiratory syncytial virus–induced respiratory failure and assesses the effect of azithromycin therapy on nasal matrix metalloproteinase 9 levels. This evidence concerns the gene MMP9 and respiratory failure.